{"id":212,"date":"2022-06-14T22:00:00","date_gmt":"2022-06-14T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=212"},"modified":"2025-09-06T12:47:15","modified_gmt":"2025-09-06T12:47:15","slug":"china-bd-2022-henlius-and-organon-enters-a-471-billion-usd-license-on-two-biosimilar-mab-assets-hlx11-and-hlx14","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/212.html","title":{"rendered":"[China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar\u00a0mAb Assets HLX11 and HLX14"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2022-06-13 (\u00a0June 13, 2022)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: Perjeta<sup>\u00ae<\/sup>\u00a0(pertuzumab, HLX11) and Prolia<sup>\u00ae<\/sup>\/Xgeva<sup>\u00ae<\/sup>\u00a0(denosumab, HLX14). <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: Shanghai Henlius Biotech\u00a0(China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Organon\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">HLX11 (anti-HER2 domain II humanized monoclonal antibody injection) is a biosimilar candidate of pertuzumab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">HLX14 (recombinant anti-RANKL human monoclonal antibody injection) is a biosimilar candidate of denosumab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pertuzumab is used for the treatment of certain patients with HER2+ breast cancer in combinations with trastuzumab and chemotherapy. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Denosumab is used for the treatment of certain patients with osteoporosis with high risk of fracture and for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Organon will license commercialization rights for biosimilar candidates referencing Perjeta<sup>\u00ae<\/sup>\u00a0(pertuzumab, HLX11) and Prolia<sup>\u00ae<\/sup>\/Xgeva<sup>\u00ae<\/sup>\u00a0(denosumab, HLX14). <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction includes an upfront payment of $73 million as well as additional payments upon the achievement of certain development, regulatory and commercial milestones.  Total up to $541 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Henlius will be responsible for development and, if approved, will supply the products to Organon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.organon.com\/news\/organon-enters-into-global-license-agreement-to-commercialize-henlius-investigational-perjeta-pertuzumab-and-prolia-xgeva-denosumab-biosimilar-candidates\/\">Organon Enters into Global License Agreement to Commercialize Henlius\u2019 Investigational Perjeta\u00ae (Pertuzumab) and Prolia\u00ae\/Xgeva\u00ae (Denosumab) Biosimilar Candidates | Organon<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Shanghai Henlius Biotech (Chinese Name: \u4e0a\u6d77\u590d\u5b8f\u6c49\u9716<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2022-06-13 (\u00a0June 13, 2022) Asset Name: Perjeta\u00ae\u00a0(pertuzumab, HLX11) and Prolia\u00ae\/Xgeva\u00ae\u00a0(denosumab, HLX14). Licensor: Shanghai Henlius &hellip; <a title=\"[China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar\u00a0mAb Assets HLX11 and HLX14\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/212.html\"><span class=\"screen-reader-text\">[China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar\u00a0mAb Assets HLX11 and HLX14<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-212","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=212"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/212\/revisions"}],"predecessor-version":[{"id":213,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/212\/revisions\/213"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}